Dr Valérie Dutoit is a tumor immunologist dedicated to the development of immunotherapeutic approaches for GBM. She completed her PhD in immunology at the Ludwig Institute for Cancer Research and graduated from the University of Lausanne in 2003. Dr Dutoit is currently Privat-Docent in the Department of Medicine at the Faculty of Medicine of the UNIGE. She is also a member of the Department of Oncology at the University Hospitals of Geneva (HUG), responsible for the Biobanking platform, Tumour Immunology Laboratory, and a member of the Steering Committee of CRTOH. She participated in the development of a novel multipeptide vaccine for GBM, which is being tested in patients, research which led the way to the development of a personalized vaccine trial for patients with GBM. She aims at understanding how immunotherapy can be combined with standard of care and what is the impact of the GBM tumor microenvironment on antitumor immune responses. She is currently working on the development of CAR T cells for GBM patients, together with the team of Prof. Migliorini from the UNIGE. Dr Dutoit is head of the biobank platform of the Oncology Service of Geneva University Hospital, a platform collecting samples from patients involved in several clinical trials and research projects with the aim to facilitate patient-oriented research.